NORTHAMPTON, MA / ACCESSWIRE / February 9, 2024 / Jazz Pharmaceuticals
By Chase Feiger, M.D.
Originally Published by Forbes
For a company to successfully create new and life-changing therapeutics for people, it must begin by establishing its own people-first and mission-driven culture. That's the premise Bruce Cozadd set out to test when he co-founded Jazz Pharmaceuticals? (NDAQ?: JAZZ) in 2003.
Jazz began its life like many other biotech startups, focused on creating therapeutics for disease areas with unmet needs, such as sleep medicine. But over the past 20 years, the company's approach evolved beyond Neuroscience to include treatment options for hematologic cancers and solid tumors. Many new pharmaceutical companies find initial success - a successful Phase 3 Clinical trial, first indication, or second indication - and quickly look for an acquirer to help them capitalize on that success. But Cozadd and Jazz have done something different, building a durable, Top 50 pharmaceutical organization, bringing over 11 therapeutics to market in the past two decades.
Continue reading here.
Bruce Cozadd, Chief Executive Office & Chairman of Jazz Pharmaceuticals ATHLONE PHOTOGRAPHY Courtesy of Forbes
View additional multimedia and more ESG storytelling from Jazz Pharmaceuticals on 3blmedia.com.
Contact Info:
Spokesperson: Jazz Pharmaceuticals
Website: https://www.3blmedia.com/profiles/jazz-pharmaceuticals
Email: info@3blmedia.com
SOURCE: Jazz Pharmaceuticals
View the original press release on accesswire.com
